~~<i id='2C4909EA12'><strike id='2C4909EA12'><tt id='2C4909EA12'><pre id='2C4909EA12'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

leisure time

author：fashion 2025-09-30 18:54:50 - browse：69949

A traditional Chinese medicine compound used for cardiac benefits might help reduce the incidence of major adverse cardiac and cerebrovascular events and even cardiac death rates, according to a new study published Tuesday in the Journal of the American Medical Association.

However, some outside experts expressed skepticism about the result.

Tongxinluo — which means “to open (tong) the network (luo) of the heart (xin)” in Mandarin — is a traditional Chinese medicine compound made out of a mixture of powders and extracts from plants, centipedes, cicadas, and other sources.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

leisure time

entertainment

hotspot

leisure time

focus

explore

ResearcherFengZhang,left,andAlexAravanis,theCEOofMoonwalk.Illustration:ChristineKao/STAT;Photo:Kathe

WSS

FDA clears AI tool for detecting skin cancer

NIH director takes cautious approach to Biden drug pricing priority

Why psychiatrists like me stop taking insurance

Federal weight loss drug coverage is 30 years out of date

EU regulator recommends expanding Mounjaro approval to obesity

Antibiotic resistance and the global rise in human conflict

hotspot

leisure time

leisure time

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

J&J to buy cancer drug developer Ambrx Biopharma

Hollywood unions extend contract negotiations for actors

JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

Cancer drug shortages should be causing more outrage

Dewpoint Therapeutics lays off staff after losing partnerships

Activists slam private health insurers over coverage restrictions

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

Hepatitis C has a cure — but many Americans still lack access to it

Copay coupons to count toward deductibles, after Biden court move

entertainment

Antibiotic resistance and the global rise in human conflict

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Goldman Sachs launches $650M fund for life science investments

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Dewpoint Therapeutics lays off staff after losing partnerships

New weight loss drugs work. But how can they best be used?

hotspot

leisure time

focus

explore